effect
rna
interferencebas
drug
depend
accumul
target
site
therapeut
relev
amount
local
administr
mucos
surfac
line
respiratori
gastrointestin
genitourinari
tract
allow
access
diseas
area
without
necess
overcom
serum
nucleas
degrad
rapid
renal
hepat
clearanc
nonspeci
fi
c
tissu
accumul
associ
system
deliveri
work
describ
rnai
therapeut
focus
pulmonari
oral
rectal
intravagin
rout
administr
mucos
barrier
compon
includ
site
variat
deliveri
consider
address
order
design
effect
mucos
deliveri
strategi
clinic
potenti
nucleic
acidbas
drug
restrict
suscept
serum
nucleas
degrad
rapid
renal
clearanc
nonspeci
fi
c
tissu
accumul
furthermor
macromolecular
polyanion
natur
reduc
interact
uptak
across
cellular
membran
requir
recruit
intracellular
rnai
machineri
improv
extracellular
intracellular
deliveri
key
therapeut
success
rnai
therapeut
chemic
modi
fi
cation
conjug
incorpor
nanoparticlebas
deliveri
system
common
strategi
employ
maximis
deliveri
rout
administr
import
determin
success
rnabas
silenc
therapeut
administr
rout
dictat
migratori
pathway
biolog
barrier
drug
must
undertak
order
reach
target
local
administr
mucos
surfac
line
respiratori
gastrointestin
genitourinari
tract
attract
altern
intraven
rout
noninvas
method
avoid
hepat
renal
clearanc
associ
system
rout
allow
direct
access
region
main
portal
entri
pathogenesi
mani
pathogen
fl
ammat
cancer
recent
phase
ii
clinic
trial
rnai
therapeut
deliv
directli
lung
highlight
potenti
support
use
mucos
rout
work
describ
pulmonari
oral
rectal
intravagin
deliveri
rnai
therapeut
focus
nanoparticlebas
deliveri
synthet
sirna
attent
given
biolog
physic
barrier
occur
mucos
surfac
restrict
uptak
lumin
materi
strategi
improv
mucos
penetr
discuss
view
better
design
mucos
deliveri
system
rnaibas
therapeut
must
overcom
physic
barrier
mucu
gel
layer
tightli
pack
epitheli
cell
combin
mucu
captur
consequ
activ
clearanc
mechan
understand
barrier
evolutionari
differ
provid
guidelin
sirnabas
therapi
target
speci
fi
c
mucos
site
section
focus
mucu
epitheli
compon
relev
nake
sirna
nanoparticlebas
sirna
deliveri
mucu
hydrat
protein
gel
overlay
lumin
surfac
mucos
site
serv
barrier
extern
environ
underli
tissu
line
respiratori
gastrointestin
genitourinari
tract
eye
fig
role
serv
fi
rst
line
defenc
variou
pathogen
toxin
facilit
continu
exchang
nutrient
water
gase
mucu
macroscop
properti
gel
exhibit
nonnewtonian
rheolog
behaviour
compos
ion
glycoprotein
term
mucin
protein
lipid
dna
cellular
debri
mucin
extend
molecul
produc
secret
goblet
cell
twolay
composit
compos
lower
steadyst
layer
contact
epithelium
mobil
outer
layer
mucu
site
variat
evolv
suit
role
perform
particular
site
mucu
thick
rate
renew
ph
properti
vari
tissu
mucu
layer
thick
determin
access
underli
epithelium
depend
lumin
condit
function
requir
underli
tissu
layer
thick
vari
along
human
gastrointestin
tract
thickest
layer
stomach
colon
eye
thick
mucu
layer
report
airway
bronchiol
access
mucos
surfac
found
nasal
region
due
thin
layer
mucu
deep
lung
epitheli
line
devoid
mucu
instead
contain
surfact
reduc
surfac
tension
potenti
ga
transfer
alveoli
relev
mucos
therapeut
deliveri
thick
integr
mucu
layer
may
compromis
variou
patholog
condit
exampl
increas
mucu
thick
observ
asthma
cystic
fi
brosi
chronic
obstruct
pulmonari
diseas
whilst
decreas
thick
observ
ulcer
coliti
variat
mucu
thick
lead
predisposit
diseas
induc
patholog
consequ
diseas
loss
epitheli
integr
seen
ulcer
coliti
despit
exist
steadi
layer
epitheli
cell
mucu
dynam
substanc
undergo
continu
renew
secret
goblet
cell
dispers
throughout
epitheli
layer
produc
outward
move
barrier
entiti
aim
reach
epitheli
layer
determin
timefram
allow
particl
penetr
epithelium
clearanc
renew
rate
tissu
depend
implic
design
therapeut
strategi
mucu
nasal
caviti
replac
approxim
everi
min
min
respiratori
tract
compar
clearanc
rate
h
gastrointestin
tract
found
rat
valu
fulli
determin
human
addit
thick
rate
renew
ph
valu
vari
differ
site
lung
nasal
mucu
nearli
neutral
eye
possess
weak
basic
ph
mucu
stomach
ph
gradient
ph
lumin
side
approxim
ph
surfac
epitheli
cell
underli
mucu
ph
variat
could
utilis
phrespons
deliveri
system
releas
cargo
speci
fi
c
mucos
site
protect
properti
mucu
pose
barrier
rnaibas
therapeut
nake
nanoparticl
form
mucu
constitu
glycoprotein
mucin
cellular
debri
lipid
form
heterogen
environ
drug
andor
drug
carrier
need
diffus
reach
target
glycosyl
domain
mucin
fi
bre
possess
neg
charg
physiolog
condit
henc
mucu
select
control
diffus
particl
particl
physic
paramet
size
also
chemic
surfac
properti
base
net
neg
charg
mucin
one
could
specul
nake
sirna
might
repel
mucin
fi
bre
multival
interact
particl
mucu
network
main
determin
particl
diffus
electrostat
hydrophob
interact
occur
possibl
make
larg
number
nonspeci
fi
c
hydrophob
interact
togeth
thermal
stabl
electrostat
interact
enabl
mucu
trap
particl
sever
studi
demonstr
ef
fi
caci
hydrophob
interact
immobilis
particl
within
mucu
ribbeck
cowork
shown
particl
surfac
charg
densiti
ph
mucin
hydrogel
alter
particl
diffus
particl
pegyl
surfac
possess
neutral
charg
greater
diffus
rate
compar
neg
posit
charg
counterpart
two
approach
govern
design
particl
mucos
deliveri
mucoadhes
mucu
penetr
approach
regard
mucoadhes
strategi
much
attent
given
design
particl
associ
mucu
barrier
henc
lower
clearanc
rate
essenc
strategi
lie
previous
mention
bilay
structur
mucu
associ
particl
lower
undisturb
layer
avoid
clearanc
enhanc
bioavail
bioactiv
entiti
anoth
posit
effect
mucu
associ
increas
viscos
due
greater
crosslink
mucu
fi
bre
turn
may
lower
clearanc
rate
materi
choic
socal
mucoadhes
materi
common
characterist
materi
adher
mucu
variou
forc
wide
use
mucoadhes
polym
chitosan
utilis
form
particl
sirna
exhibit
mucos
silenc
thiolat
polym
shown
enhanc
mucu
interact
format
disul
fi
de
linkag
mucin
variou
thiolat
chitosan
synthesis
mucoadhes
prolong
bioavail
particl
mucos
surfac
also
alter
structur
mucu
becom
permeabl
sirnaload
particl
altern
mucuspenetr
particl
limit
interact
mucu
increas
diffus
rate
excit
approach
coat
peg
demonstr
mediat
surfac
properti
latex
particl
nm
nanoparticl
compos
biodegrad
diblock
copolym
poli
sebac
acid
peg
shown
molecular
weight
degre
surfac
coverag
determin
mobil
coat
particl
report
howev
previous
classi
fi
ed
peg
mucoadhes
polym
specul
lai
et
al
contradict
report
might
attribut
variat
type
pegyl
use
use
pegcoat
particl
yet
demonstr
intracellular
deliveri
nucleic
acid
respiratori
gastrointestin
tract
interestingli
design
mucuspenetr
particl
build
lesson
learn
natur
virus
equal
surfac
densiti
posit
neg
charg
readili
penetr
mucu
barrier
thu
surfac
chemistri
togeth
size
appear
determin
factor
mucu
penetr
evid
point
toward
neutral
surfac
effect
diffus
order
array
close
pack
epitheli
cell
overlay
basement
membran
constitut
mucos
epithelium
cell
type
morpholog
arrang
differ
depend
site
function
exampl
small
intestin
compris
singlelay
enterocyt
assembl
structur
villi
increas
adsorpt
surfac
area
whilst
upper
respiratori
tract
movement
apic
cilia
pseudostrati
fi
ed
epithelium
restrict
interact
lumin
surfac
common
mucos
epithelium
close
pack
adjac
cell
separ
tight
junction
materi
uptak
across
epithelium
occur
transcellular
paracellular
pathway
determin
physicochem
characterist
materi
main
transcellular
mechan
nanoparticl
transport
across
epithelium
adsorpt
cellmedi
endocytosi
modi
fi
cation
materi
properti
target
speci
fi
c
site
use
maximis
deliveri
across
mucosa
gener
accept
tight
junction
restrict
paracellular
transport
micronanoparticl
howev
mucopenetr
enhanc
use
facilit
transient
open
junction
mediat
paracellular
movement
small
molecul
migrat
particl
local
system
tissu
reli
transloc
lymphat
vasculatur
system
depend
physicochem
properti
materi
site
diseas
pathogenesi
dictat
whether
necess
local
andor
system
deliveri
determin
therapeut
strategi
adopt
direct
access
vast
array
lungassoci
diseas
make
lung
ideal
target
rnaibas
therapi
total
surfac
area
pulmonari
rout
offer
attract
altern
invas
natur
intraven
inject
futur
clinic
potenti
pulmonari
rnai
therapeut
hold
promis
base
larg
number
current
inhal
tradit
drug
establish
pulmonari
deliveri
technolog
provid
pressuris
meter
dose
inhal
pmdi
dri
powder
inhal
dpi
respiratori
system
also
provid
opportun
drug
reach
system
circul
uptak
across
thin
epithelium
alveoli
lungassoci
diseas
fl
uenza
respiratori
syncyti
viru
rsv
infect
prime
candid
sirna
therapi
transient
natur
gene
silenc
suf
fi
cient
acut
viral
diseas
treatment
moreov
silenc
host
factor
conserv
gene
involv
viral
replic
could
overcom
necess
season
drug
direct
toward
surfac
protein
suscept
mutat
chang
sever
host
factor
critic
viral
replic
identi
fi
ed
fl
uenza
provid
select
novel
target
rnaibas
therapi
anatomi
physiolog
immunolog
lung
present
challeng
deliveri
nanoparticlebas
nake
sirna
lung
compos
conduct
respiratori
region
site
variat
structur
cell
composit
pose
speci
fi
c
region
challeng
sirna
deliveri
main
role
upper
respiratori
tract
fi
lter
conduct
air
lower
respiratori
segment
consequ
anatom
cellular
featur
restrict
materi
adsorpt
includ
nake
sirna
nanoparticlebas
deliveri
system
trachea
divid
two
primari
bronchi
carina
heavi
branch
lobular
bronchi
occur
onto
continu
narrow
tube
respiratori
segment
begin
respiratori
bronchiol
alveolar
duct
sac
deliveri
sirna
lung
whether
nake
incorpor
particl
need
address
branch
airway
mucu
layer
cover
conduct
segment
ciliat
cell
abund
nasal
caviti
trachea
apic
cilia
work
coordin
sweep
transport
mucu
along
trap
materi
toward
oesophagu
constant
remov
mucu
ciliat
cell
term
mucociliari
escal
play
critic
role
prevent
inhal
particul
pathogen
resid
within
trachea
upper
bronchiolar
tree
respiratori
mucu
consist
outer
lumin
layer
inner
layer
term
periciliari
liquid
direct
contact
cilia
normal
physiolog
condit
lumin
mucu
layer
refresh
everi
min
wherea
renew
underli
layer
clear
much
slower
mucu
layer
swept
away
replenish
continu
requir
trap
materi
nanoparticl
diffus
across
current
gradient
order
reach
epitheli
surfac
deeper
lung
mucu
layer
diminish
passageway
narrow
restrict
transit
particlebas
deliveri
system
alveoli
administ
aerosol
inertia
determin
whether
particl
impact
epithelium
wall
case
clear
mucociliari
escal
furthermor
surfact
cover
deeper
region
prevent
collaps
respiratori
section
exhal
may
interfer
particl
integr
leav
sirna
expos
enzymat
degrad
alveoli
macrophag
compens
lack
mucu
protect
abl
scaveng
foreign
materi
extend
process
lumen
alveolu
could
limit
effect
nanoparticlebas
rnai
therapeut
howev
subsequ
macrophag
migrat
may
offer
mechan
system
deliveri
nanoparticl
ongo
discuss
whether
nonformul
nake
sirna
suf
fi
cient
particl
formul
need
effect
pulmonari
sirna
deliveri
approach
use
tabl
nonformul
sirna
administ
intranas
intratrach
instil
abl
mediat
reduct
target
gene
express
viral
titr
mice
nonhuman
primat
interest
studi
bitko
et
al
demonstr
nake
phosphoproteinspeci
fi
c
antirsv
sirna
g
singl
dose
perform
near
equal
sirna
complex
commerci
transfect
agent
miru
tko
rsv
mous
model
studi
viral
titr
reduc
sever
log
intranas
administr
advers
immunostimulatori
effect
observ
alvarez
et
al
likewis
abl
reduc
rsv
titr
log
reduct
g
singl
dose
use
nake
alnylam
sirna
rsv
nucleocapsid
gene
intranas
deliveri
mice
race
analysi
cleavag
product
also
con
fi
rmed
reduct
viral
titr
fact
rnaimedi
effect
recent
result
alnylam
phase
ii
clinic
trial
publish
show
reduct
experiment
rsv
infect
test
subject
receiv
mg
compar
subject
receiv
placebo
nasal
spray
use
deliv
solut
mention
author
report
induc
rsv
infect
studi
result
mild
moder
upper
respiratori
tract
ill
region
nasal
spray
like
reach
studi
current
underway
evalu
effect
natur
infect
patient
like
use
aerosolis
deliveri
method
order
reach
upper
lower
respiratori
segment
simultan
success
achiev
studi
use
nonformul
sirna
unexpect
one
consid
polyion
natur
sirna
molecul
restrict
cellular
uptak
possibl
explan
could
loss
epitheli
integr
due
infect
might
allow
entri
nake
sirna
nonetheless
time
write
alnylam
rsv
programm
one
advanc
rnai
clinic
trial
programm
simplist
nake
sirna
approach
could
ful
fi
l
clinic
requir
costeffect
whilst
direct
administr
nake
sirna
mucosa
extens
use
suscept
duplex
serum
nucleas
make
intraven
iv
deliveri
less
attract
modi
fi
cation
sirna
backbon
howev
standard
reduc
serum
degrad
recent
studi
serum
stabil
silenc
enhanc
green
fl
uoresc
protein
egfp
bronchoepithelium
mice
demonstr
iv
administr
nake
lna
modi
fi
ed
sirna
intraven
inject
nake
lna
modi
fi
ed
sirna
fi
dose
g
sirna
result
compar
reduct
egfp
reduct
bronchoepithelium
anim
dose
intranas
chitosansirna
particl
singl
g
dose
nake
modi
fi
ed
sirna
less
effect
intranas
dose
author
suggest
success
nake
modi
fi
ed
sirna
reach
lung
epithelium
iv
inject
might
result
increas
serum
stabil
allow
longer
circul
time
compar
unmodi
fi
ed
sirna
gener
accept
nanoparticlebas
system
need
improv
therapeut
potenti
sirna
despit
success
nake
sirna
abil
packag
high
level
sirna
nanoscal
carrier
predisposit
enter
cell
promot
use
two
promin
class
polyplex
lipoplex
form
selfassembl
polyc
cation
lipid
sirna
result
ionic
interact
cation
amin
sirnabear
anion
phosphat
net
posit
charg
facilit
cellular
uptak
incorpor
mucopenetr
compon
design
promot
use
mucos
sirna
deliveri
applic
polysaccharid
chitosan
use
extens
mucos
deliveri
drug
deacetyl
deriv
natur
polym
chitin
compos
randomli
distribut
repeat
unit
b
n
acetyld
glucosamin
b
glucosamin
nontox
biocompat
biodegrad
cation
glucosamin
compon
facilit
mucoadhes
mucoperm
polyplex
format
involv
transient
open
epitheli
tight
junction
improv
paracellular
drug
transport
moreov
adher
mucu
layer
interact
sialic
acid
mucu
glycoprotein
increas
viscos
lead
decreas
mucociliari
clearanc
prolong
resid
time
cation
amin
utilis
entropydriven
format
submicron
particl
polyanion
dna
sirna
chitosan
demonstr
excel
transfect
abil
sever
vivo
studi
reveal
abil
chitosan
enhanc
respiratori
deliveri
sirna
dna
studi
et
al
achiev
express
b
galactosidas
intratrach
deliveri
chitosandna
polyplex
anoth
studi
manag
partli
immunis
mice
rsv
intranas
applic
chitosandna
particl
code
rsv
epitop
chitosanbas
nanoparticl
deliveri
sirna
fi
rst
introduc
howard
cowork
paramet
high
molecular
weight
kda
highli
deacetyl
chitosan
n
p
amin
phosphat
ratio
show
improv
format
stabil
knockdown
vitro
propos
excess
chitosan
high
n
p
ratio
may
improv
mucos
properti
silenc
enhanc
green
fl
uoresc
protein
egfp
observ
bronchiolar
epithelium
transgen
mice
intranas
administr
g
sirna
per
dose
consecut
day
chitosansirna
polyplex
intranas
administr
suffer
particl
adsorpt
mucu
layer
nasal
caviti
amount
drug
reach
lung
therefor
estim
recent
studi
group
airway
deposit
chitosansirna
particl
system
improv
aerosolis
formul
use
nebulis
cathet
trudel
medic
instrument
insert
directli
trachea
mous
silenc
target
gene
egfp
accomplish
low
dose
sirna
three
dose
g
low
dose
signi
fi
cant
step
toward
reduct
potenti
offtarget
immunolog
side
effect
chitosan
predomin
use
local
deliveri
howev
recent
report
show
chitosansirna
particl
accumul
kidney
iv
administr
suggest
circulatori
properti
furthermor
modi
fi
cation
chitosan
imidazol
group
peg
use
intraven
deliveri
sirna
mice
result
reduct
mrna
level
gapdh
lung
suggest
chitosancopolym
might
use
intraven
deliveri
vector
sinc
introduct
polyethylenimin
pei
gene
transfer
reagent
cation
polym
studi
extens
dna
sirna
deliveri
effect
polyplex
format
protect
nucleas
endosomolyt
properti
attribut
high
charg
amino
densiti
promot
use
pei
use
system
deliveri
sirna
number
tissu
includ
lung
mice
mechan
antivir
effect
studi
thoma
ge
howev
brought
question
landmark
paper
robbin
et
al
work
sever
publish
sirna
sequenc
includ
nucleocapsid
sequenc
use
ge
et
al
thoma
et
al
test
abil
stimul
innat
immun
system
ascrib
intracellular
tolllik
receptor
activ
remark
shown
control
gfp
sequenc
use
sever
vivo
studi
elicit
immun
respons
wherea
nucleocapsid
sequenc
among
other
stimul
product
interferon
suggest
larg
respons
observ
antivir
effect
abil
system
peibas
sirna
system
reach
lung
could
result
seruminduc
aggreg
consequ
entrap
within
lung
capillari
bed
howev
could
result
lung
embol
restrict
likelihood
clinic
translat
pei
unlik
chitosan
gener
thought
mucoadhes
polym
reason
specul
aminomedi
interact
mucin
occur
deliv
local
hitherto
pei
interact
effect
mucu
studi
detail
two
recent
studi
demonstr
pulmonari
egfp
silenc
transgen
mice
use
intratrach
administr
pegpeisirna
polyplex
merkel
et
al
show
reduct
egfp
express
compar
luciferas
sirna
control
singl
g
sirna
dose
moder
fl
ammat
seen
analysi
cytokin
level
histolog
abnorm
observ
beyerl
et
al
use
fatti
acid
modi
fi
ed
pegpeisirna
polyplex
achiev
reduct
egfp
express
compar
untreat
control
g
singl
dose
previou
studi
merkel
et
al
pegyl
increas
fl
ammat
whilst
time
also
decreas
cytotox
fi
nding
seem
contradict
usual
percept
peg
limit
interact
immun
system
whilst
pegyl
pegpei
polym
appear
less
cytotox
nonmodi
fi
ed
pei
fatti
acid
modi
fi
ed
pei
may
higher
proin
fl
ammatori
potenti
concern
clinic
set
although
pei
use
extens
sever
year
anim
studi
safeti
concern
still
restrict
use
clinic
lipid
vector
wide
use
vitro
vivo
deliveri
sirna
base
cation
lipid
form
lipoplex
sirna
miru
tko
cation
lipidpolym
formul
use
bitko
et
al
deliv
sirna
rsv
g
sirna
deliv
intranas
miru
tko
abl
reduc
viral
titr
mice
without
induc
interferon
respons
effect
shown
improv
nake
sirna
mous
fl
uenza
model
anim
receiv
hydrodynam
inject
nmol
nake
sirna
follow
h
later
intranas
deliv
oligofectaminesirna
nmol
complex
viral
nucleoprotein
acid
polymeras
reduc
viral
titr
lung
compar
egfp
sirna
whilst
interferon
level
investig
found
upregul
concern
remain
use
egfp
sequenc
neg
control
due
nonstimulatori
uniqu
third
commerci
lipidbas
transfect
reagent
dharmafect
use
pulmonari
deliveri
vector
bleomycininduc
lung
fi
brosi
mous
model
sirna
sparc
matricellular
protein
overexpress
fi
brotic
diseas
markedli
reduc
collagen
content
lung
compar
bleomycinonli
group
intratrach
dose
g
sirna
cation
lipid
genzym
use
mice
express
b
galactosidas
airway
epitheli
cell
reduct
mrna
level
chang
protein
level
observ
intranas
administr
lacz
sirna
g
sirna
histolog
analysi
show
lipoplex
mainli
associ
pulmonari
macrophag
could
explain
lack
chang
protein
level
direct
conjug
sirna
cholesterol
explor
moscho
et
al
singl
intratrach
administr
sirnacholesterol
conjug
nmol
facilit
knockdown
map
kinas
mrna
mous
lung
h
compar
vehicleonli
control
effect
appear
transient
detect
mrna
level
almost
back
normal
h
attribut
poor
stabil
sirna
suggest
chemic
modi
fi
cation
backbon
might
increas
silenc
effect
respiratori
vasculatur
mice
target
system
deliveri
cation
lipoplex
atuplex
reduct
endotheli
cellspeci
fi
c
protein
vecadherin
achiev
lung
intraven
inject
g
sirna
consecut
day
compar
luciferasespeci
fi
c
sirna
lipoplex
also
administ
intratrach
reduct
epitheli
ecadherin
observ
compar
luciferas
control
suggest
better
suitabl
system
deliveri
captur
within
lung
microvasculatur
subsequ
endotheli
uptak
propos
author
mechan
deliveri
anticip
clinic
translat
requir
inhal
technolog
base
aerosol
dri
powder
formul
solut
aerosol
de
fi
nition
gaseou
suspens
fi
ne
solid
particl
liquid
droplet
size
weight
particl
droplet
determin
abil
follow
fl
ow
inhal
air
airway
main
paramet
link
particl
droplet
size
weight
regard
lung
deposit
aerodynam
diamet
paramet
take
account
shape
rough
poros
particl
droplet
aerosol
aerodynam
diamet
diamet
unit
densiti
gcm
sphere
gravit
settl
veloc
particl
investig
mass
median
aerodynam
diamet
mmad
diamet
particledroplet
distribut
mass
larger
smaller
diamet
word
deposit
speci
fi
c
airway
depth
requir
achiev
given
aerodynam
diamet
eg
mmad
aerosol
total
aerosol
mass
principl
deposit
select
depth
deposit
restrict
nanoparticl
diamet
narrow
size
distribut
deposit
certain
depth
requir
investig
mmad
aerosol
typic
carri
cascad
impactor
mimick
differ
airway
depth
particl
aerodynam
diamet
like
reach
pulmonari
region
wherea
larger
particl
deposit
upper
airway
howev
particl
becom
small
prone
exhal
deposit
mean
solid
nanoparticl
per
de
fi
nition
principl
small
effect
deposit
lung
larg
portion
particl
may
end
leav
lung
inhal
two
solut
problem
either
particl
kept
solut
attach
carrier
formul
facilit
deposit
requir
depth
nanoparticl
consist
polym
sirna
form
solut
subsequ
dri
either
spray
dri
freez
dri
produc
particl
retain
silenc
abil
term
storag
stabil
therapeut
agent
might
prefer
compar
solutionbas
formul
intratrach
administr
anim
model
provid
preclin
evalu
aerosolis
sirna
formul
costeffect
inhal
chamber
nebulis
develop
speci
fi
calli
deliveri
aerosol
anim
aeroprob
trudel
medic
microspray
penncenturi
exampl
devic
use
particl
deliveri
directli
mucos
surfac
respiratori
tract
devic
overcom
dif
fi
cult
natur
mous
breath
pattern
anatomi
allow
doserespons
studi
conduct
substanti
clinic
evalu
dri
powderbas
sirna
formul
lack
although
alnylam
http
wwwalnylamcom
use
handheld
batterydriven
nebulis
system
http
wwwparipharmacom
current
phase
ii
rsv
clinic
trial
nake
sirna
promis
nanotechnolog
advanc
surfac
particl
engin
combin
recent
advanc
inhal
technolog
hold
promis
futur
inhal
sirnabas
particl
oral
administr
therapeut
consid
favour
term
costeffect
eas
administr
patient
complianc
rout
potenti
provid
rapid
system
distribut
drug
due
enorm
adsorpt
surfac
area
utilis
rout
depend
overcom
challeng
enzymat
degrad
mucu
epitheli
penetr
oral
administr
rnaibas
drug
offer
great
potenti
treatment
diseas
occur
local
within
gastrointestin
gi
tract
fl
ammatori
bowel
diseas
ibd
combat
system
patholog
condit
gi
tract
possess
specialis
epithelium
involv
degrad
macromolecul
assimil
obtain
product
restrict
transport
pathogen
unfortun
process
often
compromis
integr
absorpt
therapeut
respect
exposur
highli
activ
enzymat
environ
extrem
ph
condit
exist
selectiveperm
epitheli
barrier
main
challeng
oral
deliveri
rnai
therapeut
nucleas
highli
abund
pancreat
secret
constitut
main
enzymat
barrier
nucleic
acid
moreov
deliveri
system
may
suscept
degrad
enzym
present
lumen
eg
lipas
glycosidas
proteas
microvillu
eg
ph
extrem
along
gi
tract
rang
stomach
termin
part
small
intestin
colon
may
affect
acidor
baselabil
compon
deliveri
system
although
increas
stabil
nucleic
acid
ph
condit
achiev
chemic
modi
fi
cation
incorpor
deliveri
system
exploit
localis
ph
condit
could
offer
excit
strategi
sitespeci
fi
c
releas
sirna
use
phsensit
carrier
lumin
ph
determin
drug
ionis
degre
affect
transcellular
passiv
diffus
andor
interact
formul
compon
sinc
gi
tract
epithelium
cover
mucu
drug
must
diffus
lubric
protect
layer
order
reach
absorpt
surfac
therefor
uptak
therapeut
compound
depend
upon
interact
drug
mucu
compon
well
thick
layer
experiment
anim
model
shown
vari
along
gastrointestin
tract
whilst
paracellular
transport
across
gi
epithelium
limit
ion
small
hydrophil
molecul
diffus
across
tight
junction
hydrophob
natur
cell
membran
imped
diffus
polar
charg
molecul
consequ
macromolecular
sirna
absorpt
across
epithelia
restrict
although
bind
speci
fi
c
ligand
may
facilit
uptak
demonstr
differ
cell
type
capabl
attach
differ
chemic
compon
simpl
nucleic
acid
chemistri
could
promot
approach
nanoparticlebas
carrier
taken
adsorpt
receptormedi
endocytosi
across
enterocyt
depend
surfac
moieti
level
uptak
thought
low
although
penetr
enhanc
may
potenti
paracellular
deliveri
import
consider
deliveri
breakdown
liver
due
fi
rstpass
effect
commonli
encount
absorb
drug
altern
rout
gutassoci
lymphoid
tissu
galt
exploit
deliveri
micro
nanoparticl
overli
follicleassoci
epithelium
fae
contain
specialis
cell
term
mcell
anatom
design
sampl
lumin
particl
part
mucos
immun
respons
lymphoid
follicl
dome
highli
popul
macrophag
shown
captur
materi
system
dissemin
macrophag
propos
mechan
transport
peripher
tissu
although
particl
transport
mcell
may
augment
increas
particlesurfac
hydrophob
attach
speci
fi
c
target
ligand
import
bear
mind
utilis
rout
intestin
absorpt
galt
constitut
small
fraction
gi
tract
number
deceas
age
recent
attent
focus
transport
across
epitheli
barrier
directli
mediat
dendrit
cell
phagocyt
cell
widespread
throughout
epithelia
shown
disrupt
tight
junction
sampl
lumin
content
project
dendrit
provid
excit
opportun
design
oral
vaccin
interspeci
differ
exist
human
anim
model
commonli
use
vivo
evalu
oral
drug
administr
exampl
contrast
human
mice
rat
exhibit
less
acid
stomach
ph
vs
lower
mean
intestin
ph
import
consider
assess
clinic
translat
number
studi
use
oral
rout
sirna
deliveri
tabl
high
profi
le
studi
report
aouadi
et
al
studi
porou
b
glucan
shell
load
sirna
target
express
tumour
necrosi
factoralpha
tnfa
mitogenactiv
protein
kinas
mice
intern
element
particl
contain
trnacor
coat
consecut
layer
pei
sirna
daili
particl
administr
g
sirna
dose
oral
gavag
period
result
reduc
mrna
level
tnfa
periton
exud
cell
pec
compar
anim
receiv
scrambledsirna
contain
particl
downregul
elicit
concomit
reduct
tnfa
express
suggest
role
control
tnfa
addit
extend
knockdown
durat
day
observ
fi
nal
dose
interestingli
author
propos
sirna
releas
glucan
shell
trigger
acid
environ
phagosom
howev
could
compromis
particl
integr
low
ph
within
gi
tract
notabl
unspeci
fi
c
interferong
respons
detect
even
though
nonmodi
fi
ed
sirna
use
tnfa
silenc
macrophageenrich
cell
isol
spleen
liver
lung
tissu
observ
ascrib
particl
uptak
across
galt
subsequ
dissemin
migrat
macrophag
direct
evid
mcell
uptak
adsorpt
level
provid
howev
studi
suggest
possibl
system
silenc
via
oral
rout
certain
patholog
ibd
localis
rather
system
effect
desir
ibd
encompass
group
complex
autoimmun
diseas
broadli
categoris
crohn
diseas
ulcer
coliti
found
small
intestin
colon
respect
attract
patholog
condit
could
exploit
improv
sirnabas
therapeut
deliveri
mucosa
integr
loss
ibd
despit
numer
target
investig
includ
current
biolog
treatment
ibd
base
antitnfa
molecul
tnfa
prefer
target
oralbas
sirna
therapi
two
recent
studi
employ
oral
deliv
sirna
prevent
treatment
dextran
sodium
sulphat
dss
induc
ulcer
coliti
mice
fi
rst
studi
wilson
et
al
use
thioket
dimethylen
thioket
nanoparticl
tkn
design
trigger
antitnfa
sirna
releas
respons
rais
level
reactiv
oxygen
speci
ro
common
fl
ame
region
tenfold
speci
fi
c
decreas
colon
mrna
level
tnfa
proin
fl
ammatori
cytokin
ifng
detect
oral
administr
antitnfa
tkn
g
sirnados
consecut
day
coliti
induct
furthermor
author
also
demonstr
histolog
weight
analysi
ten
time
lower
sirna
dose
g
sirnados
suf
fi
cient
protect
mice
dssinduc
coliti
altern
approach
sitespeci
fi
c
deliveri
report
kriegel
et
al
nanoparticlesinmicrospher
oral
system
nimo
base
lipasemedi
intestin
degrad
poli
epsiloncaprolacton
microspher
trigger
releas
gelatin
nanoparticl
contain
tnfa
speci
fi
c
sirna
administr
oral
gavag
day
dss
treatment
antitnfa
sirnaload
nimo
g
sirnados
result
reduc
intestin
mrna
protein
level
compar
control
addit
elisa
show
decreas
level
sever
proin
fl
ammatori
cytokin
ifng
howev
nonspeci
fi
c
silenc
intrins
formul
observ
coliti
protect
moder
intestin
fl
ammat
healthi
colon
morpholog
evid
antitnfa
sirnatr
mice
altern
strategi
base
system
rnaibas
ibd
treatment
reveal
eleg
studi
peer
et
al
studi
iv
administr
particl
target
speci
fi
c
leucocyt
subset
b
integrin
express
gut
mononuclear
leucocyt
utilis
treatment
dssinduc
coliti
design
system
term
b
protaminesirna
core
complex
coat
within
unilamellar
vesicl
decor
antiintegrin
b
antibodi
administr
fi
c
sirna
gdose
b
day
result
reduc
intestin
mrna
level
cell
cycl
regulatori
molecul
simultan
mrna
reduct
proin
fl
ammatori
cytokin
tnfa
result
signi
fi
cantli
less
sever
lesion
intestin
tissu
revers
clinic
patholog
characterist
associ
onset
dssinduc
coliti
observ
local
effect
may
attribut
silenc
peripher
blood
spleen
leucocyt
prior
recruit
fl
ame
gut
current
evalu
potenti
sirna
nanoparticl
formul
nontox
biodegrad
mucoadhes
polym
chitosan
reduct
proin
fl
ammatori
cytokin
oral
administr
encourag
result
recent
obtain
anim
experi
suggest
strong
nucleaseprotect
high
gastrointestin
sirna
deposit
provid
system
unpublish
result
rectal
administr
attract
rout
sirna
deliveri
circumv
low
stomach
ph
establish
rout
tradit
drug
colon
present
low
enzymat
milieu
addit
direct
access
site
sever
diseas
colorect
carcinoma
ulcer
coliti
promot
rout
zhang
et
al
demonstr
rectal
administr
lipoplex
contain
antitnfa
sirna
two
dose
g
sirna
signi
fi
cantli
reduc
upregul
tnfa
mrna
dssinduc
ulcer
coliti
mous
model
reduc
perirect
tnfa
mrna
level
associ
mild
moder
fl
ammat
mucosa
descend
colon
compar
sever
fl
ammat
observ
control
interestingli
despit
toxic
previous
report
similar
liposom
formul
increas
proin
fl
ammatori
cytokin
tnfa
interferon
respons
found
later
studi
fl
uoresc
chemic
modi
fi
ed
sirna
contain
within
dotap
liposom
detect
spleen
bone
marrow
colon
liver
rectal
administr
mice
support
capabl
nanoparticl
migrat
system
circul
could
exploit
local
system
gene
silenc
advantag
establish
therapeut
rout
market
product
sustain
drug
releas
low
enzymat
activ
possibl
avoid
fi
rstpass
effect
promot
vagin
administr
sirna
poor
system
absorpt
polar
high
molecular
weight
molecul
across
epithelium
howev
seemingli
restrict
sirnabas
therapi
local
vagin
treatment
number
studi
utilis
acut
infect
mice
herp
simplex
viru
model
develop
antivir
sirnabas
therapeut
set
capac
treatment
inhibit
viral
spread
across
genit
mucosa
challeng
evalu
studi
pallis
et
al
assess
protect
provid
lipidcomplex
sirna
gdose
target
essenti
viral
gene
two
sirna
confer
signi
fi
cant
protect
consider
reduct
lethal
sever
lesion
administr
doubl
regim
h
prior
h
otherwis
lethal
vagin
challeng
protect
howev
transient
postexposur
treatment
h
viral
challeng
effect
sirna
administr
combin
individu
fl
ammatori
respons
interferon
induct
detect
histolog
express
analysi
respect
studi
exhaust
followup
studi
reveal
howev
sever
undesir
featur
toxic
side
effect
relat
lipid
formul
chemic
modi
fi
ed
sirna
approach
also
use
treatment
cholesterol
chol
sirna
conjug
stabilis
phosphorothio
residu
use
knockdown
viral
host
gene
express
consist
previou
result
target
essenti
viral
gene
exclus
confer
protect
sirna
administr
within
hour
viral
challeng
interestingli
protect
could
replic
high
sirna
dose
g
employ
matter
requir
investig
contrast
target
receptor
use
penetr
cell
confer
protect
administr
day
prior
immedi
challeng
treatment
mice
two
dose
g
dose
cholsirna
combin
target
viral
gene
provid
signi
fi
cant
protect
week
irrespect
time
challeng
woodrow
et
al
develop
deliveri
system
base
sirnapolyamin
spermidin
core
encapsul
plga
nanoparticl
singl
dose
g
particl
induc
sustain
gfp
mrna
silenc
throughout
femal
reproduct
tract
least
day
transgen
gfp
mous
model
reduct
fl
uoresc
maxim
day
vagin
tract
sirna
dose
g
releas
due
slow
degrad
rate
nanoparticl
aforement
studi
thorough
clean
vagin
tract
andor
progesteron
treatment
anim
prior
particl
administr
perform
whilst
mucu
remov
elimin
one
main
barrier
vagin
epitheli
transfect
hormon
treatment
arrest
oestrou
cycl
dioestru
phase
epithelium
thin
porou
probabl
contribut
higher
drug
absorpt
addit
treatment
associ
reduc
immun
respons
vagina
may
mask
potenti
undesir
side
effect
evalu
drug
model
close
resembl
normal
physiolog
condit
zhang
et
al
report
liposomemedi
transfect
squamou
epithelia
layer
submucosa
singl
dose
sirna
g
sirna
suf
fi
cient
induc
signi
fi
cant
consist
knockdown
target
gene
lamin
ac
period
analysi
proin
fl
ammatori
cytokin
tnfa
interferonrel
gene
detect
signi
fi
cant
chang
treat
anim
compar
control
contrast
wu
et
al
suggest
vagin
epithelium
transfect
physiolog
condit
convent
lipoplex
unlik
probabl
due
combin
poor
drug
retent
vagin
caviti
inef
fi
cient
transport
across
mucu
layer
order
overcom
limit
achiev
sustain
releas
entrap
therapeut
author
develop
characteris
system
base
biodegrad
algin
scaffold
upon
exposur
sodium
ion
common
element
cell
bodi
fl
uid
scaffold
degrad
occur
result
slow
releas
incorpor
pegyl
lipoplex
pegyl
convent
liposom
capabl
mucos
diffus
induc
sirnamedi
gene
knockdown
vagin
epithelium
intravagin
administr
scaffold
consecut
day
daili
dose
ganim
result
knockdown
lamin
ac
mrna
report
evalu
proin
fl
ammatori
cytokin
level
unspeci
fi
c
interferon
activ
report
encourag
result
recent
report
wheeler
et
al
target
viral
gag
vif
host
gene
could
inhibit
hiv
vagin
transmiss
humanis
mous
model
macrophag
tcellspeci
fi
c
target
achiev
fusion
sirna
receptorspeci
fi
c
aptam
observ
protect
probabl
due
combin
select
gene
knockdown
sirna
gag
vif
viralaptam
competit
receptor
bind
despit
appar
absenc
cellular
toxic
lymphocyt
activ
caution
taken
molecul
interact
receptor
due
role
host
immun
respons
suscept
hiv
infect
activ
lymphocyt
mucos
deliveri
rnai
therapeut
excit
approach
set
progress
rapidli
build
encourag
clinic
studi
rel
eas
access
surfac
common
pathogen
cancer
fl
ammatori
diseas
promot
use
local
deliveri
avoid
necess
instal
stealth
characterist
requir
system
deliveri
reduc
complex
design
manufactur
cost
clinic
approv
bene
fi
ts
restrict
entri
howev
encount
macromolecul
across
mucos
barrier
still
requir
deliveri
strategi
improv
penetr
context
nanoparticl
rather
nake
form
seem
promis
research
identifi
surfac
characterist
promot
mucu
penetr
includ
hydrophil
coat
set
continu
whilst
coat
mimic
pathogen
evolv
penetr
mucosa
interest
approach
detail
studi
nanoparticl
penetr
mucu
chang
mucu
morpholog
respons
mucopenetr
materi
futur
trend
variat
mucu
characterist
differ
site
diseas
state
import
consider
design
deliveri
strategi
polyplex
system
compos
sirna
cation
polym
chitosan
could
proceed
rapidli
clinic
trial
due
simplist
design
mucoadhes
mucoperm
properti
current
trend
identifi
new
biopolym
improv
mucos
deliveri
expand
select
avail
materi
recent
attent
direct
toward
oral
formul
focus
treatment
fl
ammatori
diseas
gastrointestin
tract
antiin
fl
ammatori
effect
ibd
preclin
model
use
particl
formul
suggest
ibd
primari
candid
clinic
translat
develop
biorespons
particl
coat
compos
phsensit
materi
employ
drug
type
offer
possibl
localis
sitespeci
fi
c
deliveri
utilis
differ
ph
found
throughout
gi
tract
necess
particl
disassembl
need
sirna
incorpor
cellular
rnai
machineri
call
intracellular
releas
mechan
reduc
disulphid
link
cleav
cytoplasm
strategi
cost
may
preclud
clinic
translat
contrast
necess
stabl
particl
circulatori
environ
mucos
deliveri
allow
use
less
stabl
system
could
facilit
sirna
releas
abil
nanoparticl
transloc
mucosa
enter
system
circul
set
exploit
elicit
local
system
silenc
effect
often
need
match
pathogenesi
howev
requir
modi
fi
cation
avoid
seruminduc
aggreg
hepat
clearanc
success
approach
depend
technolog
current
pursu
system
nanoparticl
deliveri
end
improv
nanoparticl
deliveri
across
lymphoid
tissu
rout
system
deliveri
set
continu
identi
fi
cation
new
target
approach
run
parallel
addit
improv
deliveri
system
sirna
design
import
consider
relev
rout
administr
initi
sirnamedi
antivir
effect
seemingli
attribut
nonspeci
fi
c
induct
innat
immun
respons
due
tolllik
receptor
tlr
engag
proin
fl
ammatori
respons
highli
detriment
particularli
fl
ammatori
disord
endocyt
pathway
undertaken
particl
increas
deliveri
tlrrich
environ
inadvert
potenti
respons
fortun
tlrdepend
signal
independ
pkr
activ
advers
side
effect
avoid
sirna
structur
sequenc
modi
fi
cation
methyl
substitut
induct
nonspeci
fi
c
immun
respons
particularli
pertin
mucos
immun
system
rich
immunocompet
site
evolv
recognis
protect
foreign
lumin
materi
evalu
immun
respons
sirna
carrier
need
adequ
address
go
forward
forese
futur
clinic
trial
set
seemingli
follow
lead
toward
treatment
pulmonari
diseas
rsv
infect
establish
pulmonari
deliveri
technolog
use
tradit
inhal
drug
allow
rapid
clinic
translat
identi
fi
cation
novel
target
push
fi
eld
forward
interest
approach
target
host
factor
requir
viral
replic
fl
uenza
rather
viralspeci
fi
c
target
gener
shift
rnai
fi
eld
convent
sirna
mirnabas
agent
set
follow
mucos
rnai
therapeut
deep
sequenc
technolog
set
use
rapid
identi
fi
cation
mucos
mirna
target
mucos
deliveri
hold
mani
advantag
system
approach
show
promis
deliveri
sirna
could
lead
rapid
clinic
translat
mucosalbas
rnai
therapeut
